You are here

  • Home
  • Archive
  • Volume 14, Issue 2
  • Nucleic acid amplification tests are more accurate and cost-effective than the Chlamydia rapid test for diagnosing genital chlamydia

Article Text

Article menu
Download PDFPDF
Health promotion
Systematic review
Nucleic acid amplification tests are more accurate and cost-effective than the Chlamydia rapid test for diagnosing genital chlamydia
  1. Thomas L Gift
  1. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  1. Correspondence to Thomas L Gift
    Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS E-80, Atlanta, GA 30333, USA; tgift{at}cdc.gov

https://doi.org/10.1136/ebn1131

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Hislop J, Quayyum Z, Flett G, et al. Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men. Health Technol Assess 2010;14:1–97, iii–iv.OpenUrlPubMedWeb of Science

    Background

    Chlamydia is the most prevalent bacterial sexually transmitted infection in the world and has been associated with reproductive sequelae in women, though the frequency with which sequelae develop is not precisely known.1 ,2 As most cases of chlamydia are asymptomatic, screening – primarily of women – has been the primary intervention used to control chlamydia.2 Screening programmes typically involve collecting a specimen from a patient, sending it to a lab for processing and notifying the patient of results and arranging treatment if positive. As Hislop and colleagues …

    View Full Text

    Footnotes

    • Disclaimer The findings and conclusions in this manuscript are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

    • Competing interests None.